Answers are grounded in this paper and cite their sources.
Insulin therapy in Type 1 diabetes is associated with weight gain. Glucagon-like peptide 1 (GLP-1) agonists, which lower blood glucose and promote weight loss, may help reverse this trend and reduce hemoglobin A1C (A1C) levels. Patients with Type 1 diabetes with concomitant GLP-1 agonists used for at least one year were included. Observed outcomes were the change in A1C, weight, and basal insulin use compared at baseline and 12 months using mixed models repeated measures. Forty-nine patients with weight gain were included. Prior to treatment, patients gained an average of 2.0 kg annually over three years. After 12 months of GLP-1 agonist therapy, weight significantly decreased from 97.6 kg (95% CI: 92.7–102.5) to 90.0 kg (95% CI: 84.9–95.1) (p < 0.001). A1C levels also improved significantly, from 8.2% (95% CI: 7.9–8.6) to 7.6% (95% CI: 7.2–7.9) (p < 0.001). Basal insulin requirements were significantly reduced. We conclude that GLP-1 agonists effectively reverse the trend of weight gain and improve A1C levels in patients with Type 1 diabetes. • The use of insulin in Type 1 diabetes is associated with weight gain. • GLP-1 agonists promote weight loss and improve diabetes outcomes in Type 2 diabetes. • The medication is currently used off-label for Type 1 diabetes. • Study shows a steady weight gain in Type 1 diabetic patients over 3.5 years. • GLP-1 agonists could reverse the trend of weight gain and improve diabetes outcomes.
No takes yet. Share an insight, caveat, or question.
Panjawatanan et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: